Inovo Inc. has relocated CHAD Therapeutics’ production and sales and marketing functions from California to Naples, Florida. Inovo acquired the oxygen conservation firm in February of this year.

 “The combination of CHAD’s leadership position and Inovo’s manufacturing expertise will allow CHAD to continue in the tradition of innovation and excellence,” said George Harris, CEO of Inovo Inc., which has manufactured regulators and conservers for the private-label market for longer than 10 years. “With 100 percent of our time and energy devoted to oxygen conservation, we are able to focus on this segment of the industry, identify needed improvements, and deliver technological advancements quickly and efficiently.”

Faced with rising delivery costs and cuts in oxygen reimbursement, HME providers are dependent upon the ability to respond quickly and effectively to changing market conditions.

“We obviously have a vested interest in their success,” states Harris, “so it is imperative that our business objectives are aligned with their needs.”